GlassScriptPhysician profile
Jenna R Pelc
NPI 1730508300
$52,626.26
in general payments reported to CMS, 2019-2025
37 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23K · 2022: $15K · 2023: $6,685 · 2024: $5,535 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,828 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,638 · Travel and Lodging: $1,106 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,828.47 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,637.50 |
| Travel and Lodging | $1,105.92 |
| Education | $198.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42,234.21 | 2021-2025 | |
| Abbott Laboratories | $1,566.15 | 2023-2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $1,398.12 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $886.42 | 2021-2022 | |
| Celgene Corporation | $636.61 | 2022-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $623.93 | 2021 | |
| Lundbeck LLC | $606.19 | 2021-2025 | Vyepti |
| Pfizer INC. | $502.78 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $492.95 | 2023-2025 | Acthar |
| Amgen INC. | $377.75 | 2021-2023 | Aimovig |
| Acadia Pharmaceuticals INC | $346.80 | 2021-2025 | Nuplazid |
| Lilly USA, LLC | $340.51 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $336.83 | 2022 | |
| Genentech USA, INC. | $290.89 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $275.55 | 2021-2024 | Rystiggo, Briviact |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $224.94 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $219.74 | 2022-2025 | Ultomiris, Soliris |
| Kyowa Kirin, INC. | $169.61 | 2021-2024 | Nourianz |
| Argenx US, INC. | $150.33 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $147.26 | 2023-2024 | |
| Biogen, INC. | $112.71 | 2024-2025 | Tysabri, Vumerity |
| Sk Life Science, INC. | $110.26 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $93.24 | 2021 | |
| Neurocrine Biosciences, INC. | $83.15 | 2023-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $60.09 | 2025 | Rexulti |
| Acorda Therapeutics, INC | $56.95 | 2023 | Inbrija, Ampyra |
| Tg Therapeutics, INC. | $45.21 | 2025 | |
| Amneal Pharmaceuticals LLC | $38.00 | 2025 | Crexont |
| Merz Pharmaceuticals, LLC | $34.33 | 2024-2025 | Inbrija, Xeomin |
| Supernus Pharmaceuticals, INC. | $34.12 | 2021 | |
| Genzyme Corporation | $31.25 | 2025 | |
| Corium, LLC | $20.68 | 2023 | Adlarity |
| E.R. Squibb & Sons, L.L.C. | $18.76 | 2022 | |
| Grifols USA, LLC | $16.99 | 2024 | Gamunex-C |
| Cala Health, INC. | $15.97 | 2025 | Cala Kiq |
| Emd Serono, INC. | $14.17 | 2025 | |
| Impel Pharmaceuticals INC. | $12.81 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Pelc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.